Systematic review with meta-analysis: early infant feeding and coeliac disease - update 2015
Autors de IIS La Fe
Autors aliens a IIS La Fe
- Szajewska H
- Shamir R
- Chmielewska A
- Piescik-Lech M
- Auricchio R
- Ivarsson A
- Kolacek S
- Koletzko S
- Korponay-Szabo I
- Mearin ML
- Troncone R
- PREVENTCD Study Group
Grups d'Investigació
Abstract
BackgroundNew evidence emerged on early feeding practices and the risk of coeliac disease. AimTo systematically update evidence on these practices to find out whether there is a need to revise current recommendations. MethodsMEDLINE, EMBASE and the Cochrane Library were searched from July 2012 (end of last search) to February 2015 for studies of any design that assessed the effect of gluten consumption and breastfeeding on the development of coeliac disease and/or coeliac disease-related autoimmunity. ResultsWe identified 21 publications, including two, new, large, randomised controlled trials performed in high-risk infants. Exclusive or any breastfeeding, as well as breastfeeding at the time of gluten introduction, did not reduce the risk of developing coeliac disease during childhood. For infants at high risk of developing coeliac disease, gluten introduction at 4months of age in very small amounts, or at 6 or 12months of age, resulted in similar rates of coeliac disease diagnosis in early childhood. Later gluten introduction was associated with later development of coeliac specific autoimmunity and coeliac disease during childhood, but not total risk reduction. Observational studies indicate that consumption of a higher amount of gluten at weaning may increase the risk for coeliac disease development. ConclusionsInfant feeding practices (breastfeeding, time of gluten introduction) have no effect on the risk of developing coeliac disease during childhood (at least at specific timeframes evaluated in the included studies), necessitating an update of current European recommendations.
Dades de la publicació
- ISSN/ISSNe:
- 0269-2813, 1365-2036
- Tipus:
- Review
- Pàgines:
- 1038-1054
- DOI:
- 10.1111/apt.13163
- PubMed:
- 25819114
- Factor d'Impacte:
- 3,079 SCImago ℠
- Quartil:
- Q1 SCImago ℠
ALIMENTARY PHARMACOLOGY & THERAPEUTICS WILEY
Cites Rebudes en Web of Science: 75
Documents
- No hi ha documents
Filiacions
Projectes associats
ANALISIS DE NUEVOS GENES IMPLICADOS EN LA PATOGENESIS DE LA ENFERMEDAD CELIACA
Investigador Principal: CARMEN RIBES KONINCKX
PI02/0573 . INSTITUTO DE SALUD CARLOS III . 2004
INNOVATIVE APPROACH FOR SELF-MANAGEMENT AND SOCIAL WELFARE OF CYSTIC FIBROSIS PATIENTS IN EUROPE: DEVELOPMENT, VALIDATION AND IMPLEMENTATION OF A TELEMATICS TOOL. MyCyFAPP
Investigador Principal: CARMEN RIBES KONINCKX
643806_H2020-PHC-2014-single-stage-MyCyFApp . COMISION EUROPEA . 2015
NUEVA ESTRATEGIA PARA LA DERIVACIÓN DE HEPATOCITOS FUNCIONALES DE MUJERES AFECTAS DE DEFICIENCIA DE ORNITINA TRANSCARBAMILASA
Investigador Principal: BERNARDO ROQUE BORT MARTÍ
SAF2014-51991-R . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2015
UN REGISTRO NO INTERVENCIONISTA A LARGO PLAZO PARA EVALUAR LA SEGURIDAD Y EFECTIVIDAD DE HUMIRA® (ADALIMUMAB) EN PACIENTES PEDIÁTRICOS CON ENFERMEDAD DE CROHN (EDC) ACTIVA ENTRE MODERADA Y GRAVE (CAPE).
Investigador Principal: ESTHER DONAT ALIAGA
P11-292 . 2015
ESTUDIO MULTICÉNTRICO, DE UN ÚNICO BRAZO, PROSPECTIVO DE 24 MESES DE DURACIÓN PARA EVALUAR LA FUNCIÓN RENAL, LA EFICACIA, LA SEGURIDAD Y LA TOLERABILIDAD DE EVEROLIMUS EN COMBINACIÓN CON UNA EXPOSICIÓN REDUCIDA DE CICLOSPORINA O TACROLIMUS EN RECEPTORES P EDIÁTRICOS DE TRASPLANTE HEPÁTICO.
Investigador Principal: CARMEN RIBES KONINCKX
CRAD001H2305 . 2013
ESTUDIO DE SEGURIDAD Y CAPACIDAD NUTRICIONAL DE UNA NUEVA FORMULA HIPOALERGICA PARA LACTANTES CON DIVERSAS FORMAS DE ALERGIA A LAS PROTEINAS DE LA LECHE DE VACA.
Investigador Principal: CARMEN RIBES KONINCKX
HER-FHT-2009-01 . 2010
A MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF LUBIPROSTONE IN PAEDIATRIC SUBJECTS AGED >= 6 YEARS TO < 18 YEARS WITH FUNCTIONAL CONSTIPATION. / ESTUDIO MULTICENTRICO, ALEATORIZADO, CONTR OLADO CON PLACEBO Y CON DOBLE ANONIMATO (DOBLE CIEGO) DE LA EFICACIA, SEGURIDAD Y FARMACOCINETICA DE LA LUBIPROSTONA EN PACIENTES PEDIATRICOS CON EDAD . 6 ANOS Y < 18 ANOS CON ESTRENIMIENTO FUNCIONAL.
Investigador Principal: CARMEN RIBES KONINCKX
SAG/0211PFC-1131
A MULTICENTRE, LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS STUDY OF LUBIPROSTONE IN PAEDIATRIC SUBJECTS AGED >= 6 TO <18 YEARS WITH FUNCTIONAL CONSTIPATION./ ESTUDIO MULTICÉNTRICO A LARGO PLAZO SOBRE LA SEGURIDAD, LA EFICACIA Y LA FARMACOCINÉTICA DE L UBIPROSTONA EN PACIENTES PEDIÁTRICOS DE EDADES COMPRENDIDAS ENTRE >= 6 AÑOS Y < 18 AÑOS CON ESTREÑIMIENTO FUNCIONAL.
Investigador Principal: CARMEN RIBES KONINCKX
SAG/0211PFC-11S1 . 2015